Attention-Deficit Hyperactivity Disorder (ADHD) patients in New Zealand are set to benefit from easier access to prescriptions as of February 1, 2026. The country's prescribing rules for stimulant medicines have been updated, expanding the range of healthcare professionals who can assess, diagnose, and initiate treatment for ADHD. This change is designed to improve the timeliness and accessibility of care for individuals living with ADHD across the nation. Previously, general practitioners (GPs) and nurse practitioners could only prescribe ADHD medications with a written recommendation from a paediatrician or psychiatrist, or after a patient had already been diagnosed and received their first prescription. Under the new guidelines, vocationally registered specialist GPs and nurse practitioners can now initiate stimulant medications for adults aged 18 and above who have been diagnosed with ADHD. Dr. Jin Russell, Chief Clinical Advisor for Child and Youth, assures that the process remains straightforward for patients seeking an ADHD assessment, emphasizing that general practices remain the initial point of contact. The updates aim to build the necessary specialist workforce and pathways to ensure safe and comprehensive assessments. While these services won't be available everywhere immediately, and not all GPs will offer them, the expanded pathways will provide more options for individuals seeking ADHD treatment. It's important to note that ADHD assessments are complex and time-consuming, typically requiring one to two hours and potentially spanning multiple appointments. The cost of these assessments will vary depending on the service type, local funding arrangements, and the duration of the assessment and follow-up. The new rules allow GPs and nurse practitioners to prescribe publicly funded stimulant medications for ADHD, including methylphenidate, dexamfetamine, and lisdexamfetamine. Dr. Russell highlights the importance of these medications, acknowledging ongoing global shortages due to high demand and limited manufacturing capacity. Pharmac is actively managing supply and exploring alternative brands and treatments to meet the increased demand. This development marks a significant step forward in making ADHD care more accessible and timely for New Zealanders, while also addressing the challenges of supply and demand in the healthcare system.
